Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval late last year. This is Napp’s first launch of a product developed ...

Amgen's longer-acting version of the drug – Neulasta (pegfilgrastim) – grew 5 per cent to approach $4.4 billion last year. That product could also be under threat, however, as it is due to ...